InsidersTradesSigma
ReShape Weightloss Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the ReShape Weightloss Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ReShape Weightloss Inc. has recorded 1 public disclosures. The latest transaction was disclosed on 22 June 2021 (J). Among the most active insiders: ARMISTICE CAPITAL, LLC. Every trade is free.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
2Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 June 2021
Declarations1 total
5,330,277 sharesCommon StockSEC:0000919574-21-004187:0
1 of 1 declaration
About ReShape Weightloss Inc.
ReShape Weightloss Inc. is a U.S.-listed healthcare company trading on the NASDAQ, focused on obesity treatment and metabolic health solutions. The business has evolved through a series of corporate and strategic steps linked to the weight-loss device industry, and it is best understood as a niche medical technology and services platform rather than a broad-based medtech group. Its operating base is in California, United States, and its commercial model is centered on physicians, bariatric specialists, and other healthcare providers serving patients with obesity and related metabolic conditions. For international investors, the company should be viewed as a small-cap healthcare name with a high dependence on product adoption, regulatory execution, and capital discipline. ReShape’s core business is built around physician-led weight-loss solutions. Its flagship offering is the Lap-Band adjustable gastric banding system, a minimally invasive surgical device used in bariatric treatment. Alongside the device franchise, the company has worked to build a broader care continuum that includes patient support and coaching services, digital engagement tools, and other products aimed at supporting medically managed weight-loss programs. This integrated approach is important strategically because it allows ReShape to position itself as a treatment platform, not just a single-product device vendor. From a competitive standpoint, ReShape operates in a difficult and fast-changing market. Bariatric surgery competes with newer obesity medications, especially GLP-1-based therapies, as well as with other surgical and non-surgical weight-management alternatives. That shift has increased pressure on many device-based obesity companies. ReShape’s response has been to streamline costs, defend its existing product portfolio, and pursue operational changes intended to improve sustainability over time. The company’s scale remains limited, and its equity story is therefore driven more by execution and turnaround potential than by established market leadership. Geographically, the company remains primarily U.S.-based, though its products and commercial relationships have historically extended into select international channels. Recent corporate highlights include a 2024 cost-reduction and reorganization plan, the introduction of Lap-Band 2.0 FLEX in 2024, and strategic actions tied to a planned merger with Vyome Therapeutics and the sale of certain assets. In investor terms, ReShape Weightloss Inc. remains a special-situation healthcare story: a NASDAQ-listed United States company with recognizable obesity-treatment assets, but also meaningful execution risk, funding sensitivity, and a challenging competitive backdrop.
